- Home
- BSLK vs MEIP Comparison
BSLK vs MEIP Comparison
Compare BSLK & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- MEIP
- Stock Information
- Founded
- BSLK 2009
- MEIP 2000
- Country
- BSLK United States
- MEIP United States
- Employees
- BSLK N/A
- MEIP N/A
- Industry
- BSLK
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- MEIP Health Care
- Exchange
- BSLK NYSE
- MEIP Nasdaq
- Market Cap
- BSLK 12.3M
- MEIP 13.3M
- IPO Year
- BSLK N/A
- MEIP 2003
- Fundamental
- Price
- BSLK $2.76
- MEIP $2.18
- Analyst Decision
- BSLK
- MEIP Hold
- Analyst Count
- BSLK 0
- MEIP 1
- Target Price
- BSLK N/A
- MEIP N/A
- AVG Volume (30 Days)
- BSLK 1.6M
- MEIP 6.4K
- Earning Date
- BSLK 05-12-2025
- MEIP 05-13-2025
- Dividend Yield
- BSLK N/A
- MEIP N/A
- EPS Growth
- BSLK N/A
- MEIP N/A
- EPS
- BSLK N/A
- MEIP N/A
- Revenue
- BSLK $1,525,000.00
- MEIP N/A
- Revenue This Year
- BSLK N/A
- MEIP N/A
- Revenue Next Year
- BSLK N/A
- MEIP N/A
- P/E Ratio
- BSLK N/A
- MEIP N/A
- Revenue Growth
- BSLK N/A
- MEIP 33.76
- 52 Week Low
- BSLK $1.75
- MEIP $1.46
- 52 Week High
- BSLK $340.40
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- MEIP 53.30
- Support Level
- BSLK N/A
- MEIP $2.05
- Resistance Level
- BSLK N/A
- MEIP $2.25
- Average True Range (ATR)
- BSLK 0.00
- MEIP 0.11
- MACD
- BSLK 0.00
- MEIP 0.00
- Stochastic Oscillator
- BSLK 0.00
- MEIP 69.91
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc develops and produces biomaterials products. Its flagship products from its Vegan Silk Technology Platform, b-silk and xl-silk, are a biodegradable and vegan protein polymer and a replacement for silicone elastomers in beauty and personal care.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.